Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX
Kiora Pharmaceuticals — Investor Presentation (November 2021)
26 slides from Kiora Pharmaceuticals's investor presentation, November 2021
Slide 1: Corporate Overview
CORPORATE OVERVIEW November 2021
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, the develop
Slide 3: Addressing Unmet Needs in Eye Care
Addressing Unmet Needs in Eye Care Compelling Value Proposition Diversified Portfolio New Leadership – Renewed Focus Revolutionary small molecule with the potential to restore vision in patients § Efficient investment to clinical inflection with inherited or age related retinal degeneration points §
Slide 4: Pipeline
Pipeline Development Stage Product Therapeutic Category Indication Anticipated Near-Term Milestones Formulation Pre-clinical Phase 1 Phase 2 Phase 3 KIO-101 Ocular Surface Disease Dry Eye Disease • Data from PoC Ph1/2a trial in Q4 2021 Eye Drop Segment Anterior KIO-201 PRK Surgical • PIND in Q1 2022
Slide 5: KIO-301
KIO-301 Small Molecule Photoswitch for Retinal Reanimation 5
Slide 6: Retinitis Pigmentosa (RP) Disease Overview
Retinitis Pigmentosa (RP) Disease Overview Prevalence § 1:3,000-1:5,000 (Orphan Disease) Etiology § 50+ genetically distinct subtypes from 150+ mutations § Inherited disease Clinical Presentation § Night blindness, reduced visual field range and eventual loss of central vision § Visual acuity declin
Slide 7: RP – How Retinal Degeneration Occurs
RP – How ReCnal DegeneraCon Occurs RGC Bipolar Cell Rod Cone To the brain (connec;on intact) Bipolar cells and RGCs relay signal from rods and Photoreceptors (rods and cones) sense light cones to the brain, where the image is “processed” and pass the signal to special transmitting cells § Normal hum
Slide 8: KIO-301 Turns RGCs “ON” in the Presence of Light
KIO-301 Turns RGCs “ON” in the Presence of Light 1. In RP, photoreceptors are no longer viable and therefore their companion “signal” cells (RGCs) are not capable of being activated or set to “OFF” 2. KIO-301 preferentially enters these “OFF” RGCs and turns them “ON” in the presence of light* KIO-31
Slide 9: KIO-301: Light Intensity and Wavelength
KIO-301: Light Intensity and Wavelength Moonlight Cloudy Day Sunlight 100w Incandescent Light Bulb Light Response Index Light Intensity (photons/cm2 · sec) Wavelength (nm) Sci. Rep. 7, 45487 (2017), Banghart, Trauner et al (2008) 9
Slide 10: KIO-301: Phase 1b Study Design
KIO-301: Phase 1b Study Design Open Label, Single Ascending Dose Trial – Royal Adelaide Hospital, Australia KIO-301 3 Paaents (NLP/LP) Cohort 1 Day 1 Single IVT dosing (single eye) X µg Day 2, 4, 7, 14, 28 Safety, pK (plasma), and efficacy Worse eye 3 Patients (NLP/LP) KIO-301 Contralateral eye of s
Slide 11: KIO-101
KIO-101 Potential 1st in Class Treatment for Dry Eye Disease 11
Slide 12: Dry Eye Overview
Dry Eye Overview A chronic, multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film § Inflammation is the common denominator of pathogenesis causing pain, irritation, light sensitivity, and more Substantial prevalence worldwide § 9 million people in Unite
Slide 13: Dry Eye Disease is Mediated by T Cells
Dry Eye Disease is Mediated by T Cells KIO-101 acts upstream to inhibit proliferation of T helper cells (Th1 and Th17) in lymph node and on-site to suppress pro-inflammatory cytokine release Arch Ophthalmol. 2012 Jan;130(1):90-100 13
Slide 14: DHODH Inhibitors
DHODH Inhibitors Validated Drug Class for Autoimmune Diseases Company Drug Status* Market / Revenue ~$2.5B annual revenue Arava (leflunomide) On market for RA Low selectivity and potency results in off-target side effects Sanofi Aubagio (teriflunomide) On market for MS § Safety concerns of severe li
Slide 15: KIO-101: Exploratory Phase 1/2a Ocular Surface Inflammation Trial
KIO-101: Exploratory Phase 1/2a Ocular Surface Inflammation Trial Dose Escalation Cohort 1: KIO-101 (0.05%) Enrolled healthy volunteers Cohort 2: KIO-101 (0.15%) (N=24, 8/cohort) Key Inclusion Criteria Cohort 3: KIO-101 (0.30%) § Ocular surface inflammaaon defined by OSDI of at least 22 Day 1 Days 8-1
Slide 16: KIO-201
KIO-201 Accelerating Ocular Surface Wound Healing 16
Slide 17: Ocular Surface Diseases
Ocular Surface Diseases Wounds: Surgery Wounds: Trauma ~5 million US patients ~2 million US patients 9% Refractive surgeries (e.g., PRK) 3% Injuries/abrasions Cataracts Chemical burns Collagen cross-linking Difficult to heal PED/ulcers Epitheliopathies: Dry Eye Epitheliopathies: Non-Dry Eye 35% ~18
Slide 18: Refractive Surgery Overview
Refractive Surgery Overview PRK The Unmet Need The Opportunity § PRK is a surgical correction of refractive § While PRK yields superior visual § Enabling the epithelium to heal faster errors for patients who are not suitable results, complications include: may mitigate peri-operative candidates for
Slide 19: KIO-201
KIO-201 § KIO-201 is based on a modified form of the natural polymer hyaluronic acid (HA) § HA is a material with a high viscosity that promotes wound healing by enabling enhanced cell migration § 5 clinical trials completed (3 PRK surgical recovery and 2 dry eye) > Approximately 400 eyes have been
Slide 20: PRK Study Design
PRK Study Design Randomize Enrolled patients KIO-201 (QID – Eye Drop) undergoing PRK Screening Measure differences in (n=234) outcomes surgery (N=250) Standard-of-Care (Bandage Contact Lens) Day 0 Day 2 Day 3 Day 4 Week 2 PRK Surgery Fluorescein Stain Fluorescein Stain Fluorescein Stain Post-surgery
Slide 21: KIO-201 Demonstrated Superiority versus BCL
KIO-201 Demonstrated Superiority versus BCL Percent of Patients with Complete Mean Wound Size (mm2) Re-Epithelialization Day 3 (Mean ± SEM) *p < 0.05 (Mean ± SEM) 8 * Recurrent Erosion 7 *p < 0.01 100% 6 § Only 1 (0.9%) study eye in 80% * 5 the KIO-201 group had recurrent erosion 4 § 4 (3.5%) study
Slide 22: Corporate Overview
Corporate Overview 22 | @KIORA
Slide 23: Executive Team
Executive Team Brian M Strem, PhD Sarah Romano, CPA Eric J Daniels, MD, MBA President & CEO Chief Financial Officer Chief Development Officer Brenda Mann, PhD Stefan Sperl, PhD Angela Den\ste, MBA VP – Research EVP – CMC & Operations VP – Clinical Opera;ons 23
Slide 24: Board of Directors
Board of Directors Paul Chaney Stephen From Ken Gayron Lead Independent Director Executive Chairman Aron Shapiro Praveen Tyle Brian M Strem, PhD President & CEO 24
Slide 25: Scientific Advisory Board
Scientific Advisory Board Daniel Durrie, MD Russel Van Gelder, MD, PhD Paul Karpecki, OD, FAAO Francis Mah, MD Quan Dong Nguyen, MD, MSc Victor Perez, MD Charlie Wykoff, MD 25
Slide 26: Contact
Contact: info@kiorapharma.com
Kiora Pharmaceuticals — Investor Presentation (November 2021) on 6ix